Zobrazeno 1 - 10
of 54
pro vyhledávání: '"J C, Ruckdeschel"'
Autor:
J. C. Ruckdeschel, S. Piantadosi
Publikováno v:
Chest. 106:324S-328
Publikováno v:
Chest. 106:348S-354
Publikováno v:
Chest. 106:367S-371
Publikováno v:
European Journal of Cancer. 34:1995-1997
Publikováno v:
The Journal of oncology management : the official journal of the American College of Oncology Administrators. 10(3)
Oncology managers increasingly need more information about how much and why treatment costs vary across cancer patients. In response to this need, our Center is building an analytic capacity for investigating economic aspects of cancer treatment. Eco
Publikováno v:
Chest surgery clinics of North America. 11(1)
The management of small-cell lung cancer (SCLC) evolved rapidly through the 1980s, but has stalled since then. The relative roles of surgery and radiotherapy in this former systemic disease have been worked out well. The chemotherapy of SCLC has prog
Publikováno v:
The cancer journal from Scientific American. 6(1)
Six of the most active chemotherapy agents in small cell lung cancer were administered sequentially in a weekly fashion in an attempt to optimize the dose and the number of agents received over a 12-week period. The purpose of this study was to estim
Autor:
M S, Tockman, J L, Mulshine, S, Piantadosi, Y S, Erozan, P K, Gupta, J C, Ruckdeschel, P R, Taylor, T, Zhukov, W H, Zhou, Y L, Qiao, S X, Yao
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 3(12 Pt 1)
The United States lung cancer epidemic has not yet been controlled by present prevention and treatment strategies. Overexpression of a Mr 31,000 protein, heterogeneous nuclear ribonucleoprotein (hnRNP) A2/B1, had shown promise as a marker of lung can
Autor:
J C, Ruckdeschel
Publikováno v:
Oncology (Williston Park, N.Y.). 12(1 Suppl 2)
Non-small-cell lung cancer (NSCLC) will increasingly come under better control as the current approaches to therapy are more broadly employed and as new therapies are deployed against recently elucidated molecular pathways. In the United States, real
Autor:
J C, Ruckdeschel
Publikováno v:
Seminars in oncology. 24(4)
Combined modality therapy of locally advanced non-small cell lung cancer has become a widely used means of treatment with several reports of benefit found in randomized phase III trials. Progress in this area may, however, be less substantive than it